These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37358619)

  • 21. Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease.
    Beyer L; Schnabel J; Kazmierczak P; Ewers M; Schönecker S; Prix C; Meyer-Wilmes J; Unterrainer M; Catak C; Pogarell O; Perneczky R; Albert NL; Bartenstein P; Danek A; Buerger K; Levin J; Rominger A; Brendel M
    Neuroimage Clin; 2019; 24():101949. PubMed ID: 31398553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
    Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
    Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ATN profile classification across two independent prospective cohorts.
    Peretti DE; Ribaldi F; Scheffler M; Mu L; Treyer V; Gietl AF; Hock C; Frisoni GB; Garibotto V
    Front Med (Lausanne); 2023; 10():1168470. PubMed ID: 37559930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum.
    Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL
    J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.
    Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW;
    Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia.
    Tan MS; Ji X; Li JQ; Xu W; Wang HF; Tan CC; Dong Q; Zuo CT; Tan L; Suckling J; Yu JT;
    Alzheimers Res Ther; 2020 May; 12(1):55. PubMed ID: 32393375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet-Derived Amyloid-β Protein Precursor as a Biomarker of Alzheimer's Disease.
    Wang Q; Shi Y; Qi X; Qi L; Chen X; Shi J; Xie C; Zhang Z
    J Alzheimers Dis; 2022; 88(2):589-599. PubMed ID: 35662121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration.
    Blazhenets G; Frings L; Ma Y; Sörensen A; Eidelberg D; Wiltfang J; Meyer PT;
    Neurology; 2021 Mar; 96(9):e1358-e1368. PubMed ID: 33408150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
    Young CB; Winer JR; Younes K; Cody KA; Betthauser TJ; Johnson SC; Schultz A; Sperling RA; Greicius MD; Cobos I; Poston KL; Mormino EC;
    JAMA Neurol; 2022 Jun; 79(6):592-603. PubMed ID: 35435938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [
    Chiotis K; Savitcheva I; Poulakis K; Saint-Aubert L; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2021 Oct; 26(10):5875-5887. PubMed ID: 32616831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
    Strikwerda-Brown C; Hobbs DA; Gonneaud J; St-Onge F; Binette AP; Ozlen H; Provost K; Soucy JP; Buckley RF; Benzinger TLS; Morris JC; Villemagne VL; Doré V; Sperling RA; Johnson KA; Rowe CC; Gordon BA; Poirier J; Breitner JCS; Villeneuve S;
    JAMA Neurol; 2022 Oct; 79(10):975-985. PubMed ID: 35907254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of tau deposition using
    Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M
    Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers.
    Baldeiras I; Silva-Spínola A; Lima M; Leitão MJ; Durães J; Vieira D; Tábuas-Pereira M; Cruz VT; Rocha R; Alves L; Machado Á; Milheiro M; Santiago B; Santana I
    J Alzheimers Dis; 2022; 90(1):419-432. PubMed ID: 36120784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroimaging biomarkers of glial activation for predicting the annual cognitive function decline in patients with Alzheimer's disease.
    Yasuno F; Kimura Y; Ogata A; Ikenuma H; Abe J; Minami H; Nihashi T; Yokoi K; Hattori S; Shimoda N; Watanabe A; Kasuga K; Ikeuchi T; Takeda A; Sakurai T; Ito K; Kato T
    Brain Behav Immun; 2023 Nov; 114():214-220. PubMed ID: 37648003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.